Even “WISE-R?”—an Update on the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation

Lili Barsky, C. Noel Bairey Merz, Janet Wei, Chrisandra Shufelt, Eileen Handberg, Carl Pepine, Thomas Rutledge, Steven Reis, Mark Doyle, William Rogers, Leslee Shaw, George Sopko

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Purpose of Review: For over 20 years, the Women’s Ischemia Syndrome Evaluation (WISE), a program sponsored by the National Heart, Lung, and Blood Institute, has explored diverse and important aspects of ischemic heart disease in women. Recent Findings: Women with symptoms and signs of ischemia but no significant epicardial obstructive coronary artery disease (INOCA) were documented to be at elevated risk for recurrent angina hospitalization, major adverse cardiac events, death, and health resource consumption rivaling those with obstructive coronary disease. Summary: WISE investigators have advanced our understanding of cardiovascular outcomes, systemic manifestations, psychological variables, socioeconomic factors, genetic contributions, hormonal status, advanced imaging, coronary functional findings, biomarkers, patient-reported outcomes, and treatments pertaining to women with this disease entity. This review delves into the WISE findings subsequent to a prior review1, postulates directions for future research, and asks are we “Even ‘WISE-R?’”.

Original languageEnglish
Article number35
JournalCurrent Atherosclerosis Reports
Issue number8
StatePublished - 1 Aug 2020
Externally publishedYes


  • Coronary microvascular dysfunction
  • Ischemic heart disease
  • Non-obstructive coronary artery disease
  • WISE


Dive into the research topics of 'Even “WISE-R?”—an Update on the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation'. Together they form a unique fingerprint.

Cite this